Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML.
In: PR Newswire, 2022-07-19
Zeitungsartikel
Zugriff:
Titel: |
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML.
|
---|---|
Zeitschrift: | PR Newswire, 2022-07-19 |
Veröffentlichung: | 2022 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|